Compare AngloGold Ashanti Limited (AU) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Crispr Therapeutics AG — how do they compare? AngloGold Ashanti Limited trades at $100.95 (market cap $49.28B), while Crispr Therapeutics AG trades at $53.96 (market cap $5.23B). The key difference: AngloGold Ashanti Limited is far larger — about 9.4× Crispr Therapeutics AG's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AU | CRSP | |
|---|---|---|
Market Cap | $49.28B | $5.23B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $76.78 |
52-Week Low | $52.15 | $44.34 |
Enterprise Value | $48.29B | $3.65B |
Dividend Yield | 4.64% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
